26,295 results on '"Liver fibrosis"'
Search Results
2. Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
3. Early Liver Disease Breath Detection
4. Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (SOPRANO)
5. Different Doses of ZED1227 vs. Placebo in NAFLD (NormaliZED)
6. Pediatric Liver Transplantation-Liver Fibrosis Evaluation by Using Fibrosis Panel (PT-LiFE)
7. Fibrosis Lessens After Metabolic Surgery (FLAMES)
8. Pirfenidone and Advanced Liver Fibrosis. (PROMETEO)
9. Survivin inhibition ameliorates liver fibrosis by inducing hepatic stellate cell senescence and depleting hepatic macrophage population.
10. The Origin and Fate of Liver Myofibroblasts
11. Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
12. Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis (KETONASH)
13. Quantitative Diagnosis of Liver Fibrosis on Multiparametric MRI
14. Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
15. Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
16. Development of Novel MRI Methods for Detecting, Discriminating, and Measuring Liver Fibrosis and Congestion in Fontan Patients
17. Early Detection of Advanced Fatty Liver Disease
18. Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis. (ODISEA)
19. Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
20. Association of hsCAR With MAFLD and Liver Fibrosis: A Cross-sectional Study
21. T1rho Imaging of Liver in Presence of Iron
22. HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.
23. Bariatric Endoscopy and NAFLD
24. Hydroxynidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
25. FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE) (FORCE)
26. ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial
27. Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment.
28. Lactylation signature identifies liver fibrosis phenotypes and traces fibrotic progression to hepatocellular carcinoma.
29. Epitranscriptomic regulation of lipid oxidation and liver fibrosis via ENPP1 mRNA m6A modification.
30. Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology.
31. Apoptotic vesicles (apoVs) derived from fibroblast-converted hepatocyte-like cells effectively ameliorate liver fibrosis.
32. Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: a nationally representative cross-sectional study using NHANES data from 2017 to 2020
33. A branched polymer-based agent for efficient and precise targeting of fibrosis diseases by magnetic resonance imaging.
34. Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA‐C).
35. Forsythiaside-A improved bile-duct-ligation-induced liver fibrosis in mice: The involvement of alleviating mitochondrial damage and ferroptosis in hepatocytes via activating Nrf2.
36. Liver fibrosis analysis using digital pathology.
37. Elastography—The New Standard in the Assessment of Fibrosis After Pediatric Liver Transplantation?
38. Angiocrine signaling in sinusoidal homeostasis and liver diseases.
39. FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond.
40. Head-to-Head Comparison of Hepatic Vein and Superior Vena Cava Flow Velocity Waveform Analyses for Predicting Elevated Right Atrial Pressure.
41. Farnesoid X receptor modulator 12β-(m-methyl-benzoyl)-11,12-dihydro oleanolic acid represses liver fibrosis by inhibiting ERK/p38 signaling pathways.
42. Heterogeneous Pathological Changes in Liver Lobes During Liver Disease: A Perspective Review.
43. Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017–2018.
44. Comparison of transient elastography and shear wave elastography in patients with MAFLD: A single-center experience.
45. Magnetic Resonance Elastography of Liver: Current Status and Future Directions.
46. Assessment of Metabolic and Bariatric Surgery Safety in Patients with Advanced Liver Fibrosis.
47. Low muscle quality index is associated with increased risk of advanced fibrosis in adult patients with nonalcoholic fatty liver disease: NHANES 2011–2014.
48. Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation.
49. Smart Microneedle Arrays Integrating Cell‐Free Therapy and Nanocatalysis to Treat Liver Fibrosis.
50. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunctionassociated steatotic liver disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.